Clinical, Molecular and Physiopathological Study of Cohen Syndrome and Cohen-like Syndromes

January 30, 2018 updated by: Centre Hospitalier Universitaire Dijon
This project will make it possible to better understand the natural history of Cohen Syndrom and the phenotypes associated with mutations in the VPS13B gene, to improve the therapeutic management of patients. It will also provide a better description of Cohen-like syndrome for genetic counselling for the families concerned.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Dijon, France, 21079
        • CHU de Dijon

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Cohen syndrome

Description

Inclusion Criteria:

  • Patients presenting Cohen syndrome and two VPS13B mutations
  • who accept a clinical evaluation, and to provide at least one blood sample
  • Patients presenting the diagnostic criteria of Cohen syndrome, but without a VPS13B mutation
  • Patients presenting neutropenia or pigmentary retinopathy and at least one of the following signs, after exclusion of any other syndrome: mental retardation, microcephaly, truncal obesity

Exclusion Criteria:

  • - Patients who do not meet the clinical and/or molecular criteria
  • Patients who do not wish to provide a blood sample for question 1,
  • Patients who have not provided written informed consent,
  • Pregnant or breast-feeding women,
  • Persons not covered by National Health Insurance and persons under guardianship or in prison.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
- Patients presenting Cohen syndrome and two VPS13B mutations
Patients presenting Cohen syndrome without a VPS13B mutation
Patients presenting neutropenia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
spectrum of mutations VPS13B
Time Frame: baseline
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 24, 2013

Primary Completion (Actual)

September 13, 2016

Study Completion (Actual)

September 13, 2016

Study Registration Dates

First Submitted

July 17, 2013

First Submitted That Met QC Criteria

July 22, 2013

First Posted (Estimate)

July 25, 2013

Study Record Updates

Last Update Posted (Actual)

January 31, 2018

Last Update Submitted That Met QC Criteria

January 30, 2018

Last Verified

January 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • OLIVIER-FAIVRE PHRC N 2012

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cohen Syndrome

3
Subscribe